Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Charter Communications
CHTR
|
+$601M |
| 2 |
Parker-Hannifin
PH
|
+$576M |
| 3 |
JPMorgan Chase
JPM
|
+$575M |
| 4 |
Goldman Sachs
GS
|
+$452M |
| 5 |
FedEx
FDX
|
+$371M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$733M |
| 2 |
American Tower
AMT
|
+$684M |
| 3 |
Nike
NKE
|
+$601M |
| 4 |
AGN
Allergan plc
AGN
|
+$561M |
| 5 |
McDonald's
MCD
|
+$536M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.7% |
| 2 | Consumer Discretionary | 17.46% |
| 3 | Healthcare | 13.37% |
| 4 | Communication Services | 12.12% |
| 5 | Financials | 11.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
Spyre Therapeutics
SYRE
$8.69B
| $6.29M | 0.01% |
57,829
+831
| +1% | +$121K |
|
502
iRhythm Holdings
IRTC
$3.69B
| $6.16M | 0.01% |
+205,294
| New | +$5.53M |
|
|
SAGE
503
PUT
DELISTED
Sage Therapeutics
SAGE
| $6.13M | 0.01% |
+120,000
| New | +$5.66M |
|
|
TRHC
504
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $6.07M | 0.01% |
405,194
+135,529
| +50% | +$1.73M |
|
505
Terex
TEX
$7.89B
| $5.93M | 0.01% |
+188,015
| New | +$5.21M |
|
506
WSFS Financial
WSFS
$4.14B
| $5.71M | 0.01% |
123,298
+2,430
| +2% | +$97.7K |
|
507
PUT
iShares Biotechnology ETF
IBB
$9.44B
| $5.59M | 0.01% |
63,147
+41,832
| +196% | +$3.81M |
|
|
BOLD
508
DELISTED
Audentes Therapeutics, Inc
BOLD
| $5.47M | 0.01% |
299,656
+1,070
| +0.4% | +$18.5K |
|
509
Regenxbio
RGNX
$622M
| $5.42M | 0.01% |
292,268
+246
| +0.1% | +$4.7K |
|
|
CACB
510
DELISTED
Cascade Bancorp
CACB
| $5.29M | 0.01% |
651,388
+29,746
| +5% | +$206K |
|
|
FENX
511
DELISTED
Fenix Parts, Inc.
FENX
| $5.18M | 0.01% |
1,838,352
+31,028
| +2% | +$106K |
|
512
Amgen
AMGN
$203B
| $5.13M | 0.01% |
+35,067
| New | +$5.28M |
|
513
FB Financial Corp
FBK
$2.94B
| $5.06M | 0.01% |
194,990
+19,990
| +11% | +$457K |
|
514
IBM
IBM
$204B
| $5.03M | 0.01% |
31,683
+14,418
| +84% | +$2.2M |
|
515
PUT
iShares US Healthcare ETF
IYH
$3.38B
| $4.94M | 0.01% |
171,430
+107,930
| +170% | +$3.13M |
|
|
ALXN
516
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
| $4.89M | 0.01% |
+40,000
| New | +$4.89M |
|
|
TCP
517
DELISTED
TC Pipelines LP
TCP
| $4.83M | 0.01% |
82,145
+6,921
| +9% | +$373K |
|
|
LJPC
518
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $4.52M | 0.01% |
257,709
| – | – |
|
519
AT&T
T
$167B
| $4.23M | ﹤0.01% |
131,766
-1,220,292
| -90% | -$36M |
|
|
TRVN
520
DELISTED
Trevena, Inc.
TRVN
| $4.15M | ﹤0.01% |
1,129
+3
| +0.3% | +$10.7K |
|
521
PepsiCo
PEP
$191B
| $3.99M | ﹤0.01% |
38,125
+7,780
| +26% | +$815K |
|
522
MacroGenics
MGNX
$254M
| $3.86M | ﹤0.01% |
188,908
-6,203
| -3% | -$156K |
|
|
DFS
523
DELISTED
Discover Financial Services
DFS
| $3.85M | ﹤0.01% |
53,396
-856
| -2% | -$54.4K |
|
524
Ventas
VTR
$48.7B
| $3.77M | ﹤0.01% |
+60,322
| New | +$3.82M |
|
525
Baxter International
BAX
$12.1B
| $3.69M | ﹤0.01% |
83,107
+11,436
| +16% | +$529K |
|
Similar funds
Jennison Associates's Q4 2016 Portfolio in Review
As of Q4 2016, Jennison Associates held 857 positions worth $89.6B, down 3.4% from $92.8B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Jennison Associates withdrew a net $3.76B in Q4 2016, closing 52 positions and reducing 313 holdings. Its most notable exit was lululemon athletica, an estimated $342M position sold in full.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Jennison Associates opened a new position in Parker-Hannifin worth $606M.
- Jennison Associates's largest Q4 2016 buy was Parker-Hannifin: 4,330,276 shares worth $606M.
- Jennison Associates added most to Charter Communications in Q4 2016, an estimated $601M increase.
- Jennison Associates's biggest Q4 2016 reduction was Biogen, cutting an estimated $733M.
- Jennison Associates fully exited lululemon athletica in Q4 2016, selling an estimated $342M.
- Jennison Associates's ten largest holdings make up 25% of its $89.6B portfolio in Q4 2016.
- Jennison Associates opened 208 new positions and closed 52 in Q4 2016.
- Jennison Associates's portfolio value fell 3.4% quarter-over-quarter to $89.6B.
Based on Jennison Associates's 13F filing for Q4 2016, filed 6 Feb 2017.